文献速递免疫规划卫生政策与健康促进

寨卡疫苗对育龄期女性的潜在经济价值

The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age.
PubMed 文献 · Am J Prev Med · 2020-01-21

研究采用马尔可夫模型模拟育龄期女性寨卡感染风险与临床过程,评估疫苗接种的成本效果。当感染风险≥0.05%-0.08%、疫苗效力≥25%、接种成本为1-7500美元时,接种具有成本效果;在特定条件下接种可节省成本并带来健康收益。

要点

  • 感染风险≥0.05%-0.08%、疫苗效力≥25%、成本1-7500美元时接种具成本效果。
  • 感染风险≥0.1%且效力≥75%时接种可节省成本并改善健康。
  • 感染风险≥0.5%且效力≥25%时接种可节省成本并改善健康。

核心结论

  • 疫苗接种具有成本效果和节省成本的阈值可为寨卡疫苗研发和实施提供目标。

研究设计与样本

  • 开发马尔可夫模型模拟育龄期女性寨卡感染的潜在风险和临床过程。
  • 模型代表2019年情况,使用美元和国际美元,地区为美洲区域。

主要发现

  • 与不接种相比,当感染风险≥0.05%-0.08%(随国家收入变化)、疫苗效力≥25%、接种成本为1-7500美元(国际美元5-10000,取决于国家收入水平)时,接种具有成本效果,增量成本效果比为每避免一个伤残调整生命年1254-82900美元。
  • 当感染风险≥0.1%且疫苗效力≥75%、或感染风险≥0.5%且疫苗效力≥25%时,在疫苗提供1年保护期且成本≤200美元的情景下,接种占优势(即节省成本并提供有益健康效果)。
  • 在某些情况下,当风险低至0.015%、成本高达7500美元(国际美元10000)、效力低至25%、保护期为1年时,疫苗仍具有成本效果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: With Zika vaccine candidates under development and women of childbearing age being the primary target population, now is the time to map the vaccine (e.g., efficacy and duration of protection) and vaccination (e.g., cost) characteristic thresholds at which vaccination becomes cost effective, highly cost effective, and cost saving. METHODS: A Markov model was developed (to represent 2019 circumstances, US$ and INT$, Region of the Americas) to simulate a woman of childbearing age and the potential risk and clinical course of a Zika infection. RESULTS: Compared with no vaccination, vaccination was cost effective (incremental cost-effectiveness ratio: US$1,254-$82,900/disability-adjusted life years averted) when the risk of infection was ≥0.05%-0.08% (varying with country income), vaccine efficacy was ≥25%, and vaccination cost was US$1-$7,500 (INT$5-$10,000 depending on country income level). Vaccination was dominant (i.e., saved costs and provided beneficial health effects) when the infection risk was ≥0.1% for a vaccine efficacy ≥75% and when the infection risk was ≥0.5% for a vaccine efficacy ≥25%, for scenarios where vaccination conferred a 1-year duration of protection and cost ≤$200. In some cases, the vaccine was cost effective when the risk was as low as 0.015%, the cost was as high as $7,500 (INT$10,000), the efficacy was as low as 25%, and the duration of protection was 1 year. CONCLUSIONS: The thresholds at which vaccination becomes cost effective and cost saving can provide targets for Zika vaccine development and implementation.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Bartsch SM, Asti L, Stokes-Cawley OJ, et al. The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age. Am J Prev Med. 2020. PMID: 31980305. doi:10.1016/j.amepre.2019.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。